Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2025)

Barinthus Biotherapeutics' Other Non-Current Liabilities history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 8.53% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 8.53%, while the annual FY2025 figure was $1.5 million, 8.53% up from the prior year.
  • Other Non-Current Liabilities reached $1.5 million in Q4 2025 per BRNS's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.7 million in Q1 2025 to a low of $434000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.5 million, with a median of $1.5 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: fell 27.84% in 2022, then soared 294.01% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.4 million in 2021, then dropped by 27.84% to $1.7 million in 2022, then decreased by 22.56% to $1.3 million in 2023, then grew by 2.64% to $1.4 million in 2024, then increased by 8.53% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Other Non-Current Liabilities are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).